8 research outputs found

    Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial

    Get PDF
    Objective: The HOME BP (Home and Online Management and Evaluation of Blood Pressure) trial aimed to test a digital intervention for hypertension management in primary care by combining self-monitoring of blood pressure with guided self-management. Design: Unmasked randomised controlled trial with automated ascertainment of primary endpoint. Setting: 76 general practices in the United Kingdom. Participants: 622 people with treated but poorly controlled hypertension (>140/90 mm Hg) and access to the internet. Interventions: Participants were randomised by using a minimisation algorithm to self-monitoring of blood pressure with a digital intervention (305 participants) or usual care (routine hypertension care, with appointments and drug changes made at the discretion of the general practitioner; 317 participants). The digital intervention provided feedback of blood pressure results to patients and professionals with optional lifestyle advice and motivational support. Target blood pressure for hypertension, diabetes, and people aged 80 or older followed UK national guidelines. Main outcome measures: The primary outcome was the difference in systolic blood pressure (mean of second and third readings) after one year, adjusted for baseline blood pressure, blood pressure target, age, and practice, with multiple imputation for missing values. Results: After one year, data were available from 552 participants (88.6%) with imputation for the remaining 70 participants (11.4%). Mean blood pressure dropped from 151.7/86.4 to 138.4/80.2 mm Hg in the intervention group and from 151.6/85.3 to 141.8/79.8 mm Hg in the usual care group, giving a mean difference in systolic blood pressure of −3.4 mm Hg (95% confidence interval −6.1 to −0.8 mm Hg) and a mean difference in diastolic blood pressure of −0.5 mm Hg (−1.9 to 0.9 mm Hg). Results were comparable in the complete case analysis and adverse effects were similar between groups. Within trial costs showed an incremental cost effectiveness ratio of £11 ($15, €12; 95% confidence interval £6 to £29) per mm Hg reduction. Conclusions: The HOME BP digital intervention for the management of hypertension by using self-monitored blood pressure led to better control of systolic blood pressure after one year than usual care, with low incremental costs. Implementation in primary care will require integration into clinical workflows and consideration of people who are digitally excluded. Trial registration: ISRCTN13790648

    Angular analysis of D0π+πμ+μD^0 \to \pi^+\pi^-\mu^+\mu^- and D0K+Kμ+μD^0 \to K^+K^-\mu^+\mu^- decays and search for CPCP violation

    No full text
    The first full angular analysis and an updated measurement of the decay-rate CPCP asymmetry of the D0π+πμ+μD^0 \to \pi^+\pi^-\mu^+\mu^- and D0K+Kμ+μD^0 \to K^+K^-\mu^+\mu^- decays are reported. The analysis uses proton-proton collision data collected with the LHCb detector at centre-of-mass energies of 7, 8 and 13 TeV. The data set corresponds to an integrated luminosity of 9 fb1^{-1}. The full set of CPCP-averaged angular observables and their CPCP asymmetries are measured as a function of the dimuon invariant mass. The results are consistent with expectations from the Standard Model and with CPCP symmetry

    Study of Bc+ {\mathrm{B}}_{\mathrm{c}}^{+} decays to charmonia and three light hadrons

    No full text
    International audienceUsing proton-proton collision data, corresponding to an integrated luminosity of 9 fb1^{−1} collected with the LHCb detector, seven decay modes of the Bc+ {\mathrm{B}}_{\mathrm{c}}^{+} meson into a J/ψ or ψ(2S) meson and three charged hadrons, kaons or pions, are studied. The decays Bc+ {\mathrm{B}}_{\mathrm{c}}^{+} → (ψ(2S) → J/ψπ+^{+}π^{−}+^{+}, Bc+ {\mathrm{B}}_{\mathrm{c}}^{+} → ψ(2S)π+^{+}π^{−}π+^{+}, Bc+ {\mathrm{B}}_{\mathrm{c}}^{+} → J/ψK+^{+}π^{−}π+^{+} and Bc+ {\mathrm{B}}_{\mathrm{c}}^{+} → J/ψK+^{+}K^{−}K+^{+} are observed for the first time, and evidence for the Bc+ {\mathrm{B}}_{\mathrm{c}}^{+} → ψ(2S)K+^{+}K^{−}π+^{+}, decay is found, where J/ψ and ψ(2S) mesons are reconstructed in their dimuon decay modes. The ratios of branching fractions between the different Bc+ {\mathrm{B}}_{\mathrm{c}}^{+} decays are reported as well as the fractions of the decays proceeding via intermediate resonances. The results largely support the factorisation approach used for a theoretical description of the studied decays.[graphic not available: see fulltext

    Constraints on the CKM angle γ\gamma from B±Dh±B^\pm\rightarrow Dh^\pm decays using Dh±hπ0D\rightarrow h^\pm h^{\prime\mp}\pi^0 final states

    No full text
    A data sample collected with the LHCb detector, corresponding to an integrated luminosity of 9 fb19~{\rm fb}^{-1}, is used to measure CPCP observables in B±Dh±B^\pm \to D h^\pm decays, where h()h^{(\prime)} is either a kaon or a pion, and the neutral DD meson decay is reconstructed in the three-body final states K±ππ0K^\pm \pi^\mp \pi^0, π±ππ0\pi^\pm \pi^\mp \pi^0, and K±Kπ0K^\pm K^\mp \pi^0. The most suppressed of these modes, B±[π±Kπ0]DK±B^\pm \to [\pi^\pm K^\mp \pi^0]_D K^\pm, is observed with a significance greater than seven standard deviations and constraints on the CKM angle γ\gamma are calculated from the combination of the measurements

    Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma.

    Get PDF
    Concentrations of liver enzymes in plasma are widely used as indicators of liver disease. We carried out a genome-wide association study in 61,089 individuals, identifying 42 loci associated with concentrations of liver enzymes in plasma, of which 32 are new associations (P = 10(-8) to P = 10(-190)). We used functional genomic approaches including metabonomic profiling and gene expression analyses to identify probable candidate genes at these regions. We identified 69 candidate genes, including genes involved in biliary transport (ATP8B1 and ABCB11), glucose, carbohydrate and lipid metabolism (FADS1, FADS2, GCKR, JMJD1C, HNF1A, MLXIPL, PNPLA3, PPP1R3B, SLC2A2 and TRIB1), glycoprotein biosynthesis and cell surface glycobiology (ABO, ASGR1, FUT2, GPLD1 and ST3GAL4), inflammation and immunity (CD276, CDH6, GCKR, HNF1A, HPR, ITGA1, RORA and STAT4) and glutathione metabolism (GSTT1, GSTT2 and GGT), as well as several genes of uncertain or unknown function (including ABHD12, EFHD1, EFNA1, EPHA2, MICAL3 and ZNF827). Our results provide new insight into genetic mechanisms and pathways influencing markers of liver function

    Observation of the rare Bs0oμ+μB^0_so\mu^+\mu^- decay from the combined analysis of CMS and LHCb data

    No full text
    corecore